Prevalence of cervical cancer in the Far Eastern Federal District and ways to improve early detection of the disease

Belokrinitskaya T.E., Filippov O.S., Frolova N.I.

1) Chita State Medical Academy of the Ministry of Health of Russia, Chita, Russia; 2) A.I. Evdokimov Moscow State University of Medicine and Dentistry of Minzdrav of Russia, Moscow, Russia
Aim. To investigate the prevalence, mortality, and detection rate of cervical cancer in the Far Eastern Federal District for the development and implementation of a cervical cancer screening program aimed to reduce mortality in the female population.
Materials and methods. The study used statistical and analytical methods, including a retrospective analysis of official statistical indicators for cervical cancer in eight federal districts of the Russian Federation and 11 subjects of the Far Eastern Federal District, with a subsequent mathematical interpretation of the data. Mean values ​​were calculated according to the generally accepted statistical methods.
Results. In the Far Eastern Federal District, incidence rates of cervical cancer for the years 2014–2017 ranged from 17.33 to 21.36 per 100,000 of female population, which were greater than that in the Russian Federation (from 14.47to 15.76, respectively). In 2018, the Far East Federal District had the highest prevalence of cervical cancer in the Russian Federation (152.3 vs.123.7 per 100,000 of female population). Regional problems include low cervical screening coverage for the female population aged 21–69 at 50.53% (CI 10.0–78.7%) (target> 70%) and active detection of cervical cancer at 48.58% ( CI 33.51–66.7%) (target indicator for stage I – II cervical cancer identifiable by visual inspection> 70%).
Conclusion. The Far Eastern Federal District has the highest prevalence of cervical cancer, which requires the active implementation of an organized cervical screening program based on human papillomavirus and cytology co-testing and accessible to people living in remote rural areas of the region.

Keywords

cervical cancer
incidence
mortality
diagnosis
screening

References

  1. Bruni L., Albero G., Serrano B., Mena M., Gómez D., Muñoz J. et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report. 2019. 315 p. URL: https://www.hpvcentre.net/statistics/reports/XWX.pdf
  2. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2018 году. М., 2019. 236 с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. The state of cancer care in Russia in 2018. Moscow, 2019. 236 p. (in Russian)].
  3. Schiffman M., Doorbar J., Wentzensen N., de Sanjosé S., Fakhry C., Monk B.J. et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016; 2: 16086. doi: 10.1038/nrdp.2016.86.
  4. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки: руководство для врачей. Изд. 3-е. М.: МЕДпресс-информ, 2012. 190c. [Sukhykh G.T., Prilepskaya V.N., ed. Prevention of cervical cancer: a guide for doctors. Ed. 3-rd. M.: Medpress-inform. 2012. 190p. (in Russian)].
  5. WHO guidance note: comprehensive cervical cancer prevention and control: a healthier future for girls and women. World Health Organization; 2013. 13 р.
  6. Каприн А.Д., Новикова Е.Г., Трушина О.И., Грецова О.П. Скрининг рака шейки матки – нерешенные проблемы. Исследования и практика в медицине. 2015; 2(1): 36–41. [Kaprin A.D., Novikova E.G., Trushina O.I., Gretzova O.P. The cervical cancer screening – unsolved problems. Issledovaniya i praktika v medicine / Research’ N Practical Medicine Journal. 2015; 2(1): 36–41. (in Russian)]. DOI:10.17709/2409-2231-2015-2-1-36-41
  7. Фролова Н.И., Белокриницкая Т.Е., Баркан Т.М., Голыгин Е.В., Лига В.Ф., Плетнева В.А. и др. Медико-социальная характеристика женщин молодого фертильного возраста, перенесших гистерэктомию. Acta Biomedica Scientifica. 2018; 3(4): 15–20. [Frolova N.I., Belokrinitskaya T.E., Barkan T.M., Golygin E.V., Liga V.F., Pletneva V.A. et al. Medical and social characteristics of women of young reproductive age after hysterectomy. Acta Biomedica Scientifica, 3 (4): 15-20. (in Russian)]. doi: 10.29413/ ABS.2018-3.4.2
  8. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М., 2018. 250 с. [Kaprin A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow, 2018. 250 p.(in Russian)]
  9. Адамян Л.В., Артымук Н.В., Белокриницкая Т.Е., Корженкова Г.П., Протасова А.Э., Рожкова Н.И. и др. Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака. Клинические рекомендации (протоколы лечения). Проблемы репродукции. 2018; 24(S6): 775–802. [Adamyan L.V., Artymuk N.V., Belokrinitskaya T.E., Korzhenkova G.P., Protasova A.E., Rozhkova N.I. et al. Benign and precancerous diseases of the cervix from the position of cancer prevention. Clinical recommendations (treatment protocols). Problemy reproduktsii/Russian Journal of Human Reproduction 2018; 24(S6): 775–802. (in Russian)]
  10. Белокриницкая Т.Е., Фролова Н.И., Туранова О.В., Шемякина К.Н., Плетнева В.А. и др. Результативность и приемлемость обследования на вирус папилломы человека при самостоятельном и врачебном заборе вагинального отделяемого. Акушерство и гинекология. 2017; 2: 97–105. [Belokrinitskaya T.E., Frolova N.I., Turanova O.V., Shemyakina K.N., Pletneva V.A. et al. The effectiveness and acceptability of screening for human papillomavirus in self- and medical sampling of vaginal discharge. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; 2: 97–105 (in Russian)] http://dx.doi.org/10.18565/aig.2017.2.97–105
  11. Chou H.H., Huang H.J., Cheng H.H., Chang C.J., Yang L.Y., Huang C.C. et al. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J Formos Med Assoc. 2016; 115(12): 1089–96. doi: 10.1016/j.jfma.2015.10.014.
  12. Verdoodt F., Jentschke M., Hillemanns P., Racey C.S., Snijders P.J., Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015; 51(16): 2375–85. doi: 10.1016/j.ejca.2015.07.006.
  13. von Karsa L., Arbyn M., De Vuyst H., Dillner J., Dillner L., Franceschi S. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015; 1: 22–31. doi:10.1016/j.pvr.2015.06.006

Received 11.12.2019

Accepted 25.12.2019

About the Authors

Tatiana E. Belokrinitskaya, MD, PhD, Professor, the head of the Obstetrics and Gynecology Department, Chita State Medical Academy, Ministry of Health of Russian.
Email: tanbell24@mail.ru
672000, Russia, Chita, Gorky str. 39a.
Oleg S. Filippov, MD, PhD, Professor, Deputy Director of the Department of medical care to children and mothers, Ministry of Health of Russia, Professor of the Reproductive Medicine and Surgery Department of the Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Ministry of Health of Russia. Address: E-mail: filippovos@rosminzdrav.ru; https://orcid.org/0000-0003-2654-1334
127994, Russia, Moscow, Rakhmanovsky str., 3.
Nataly I. Frolova, Assistant of Professor, Obstetrics and Gynecology Department, Chita State Medical Academy, Ministry of Health of Russian. Email: taasyaa@mail.ru,
https://orcid.org/0000-0002-7433-6012
672090, Russia, Chita, Gorky str. 39a.

For citation: Belokrinitskaya T.E., Filippov O.S., Frolova N.I. Prevalence of cervical cancer in the Far Eastern Federal District and ways to improve early detection of the disease.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 1(Suppl):63-8. (in Russian)
https://dx.doi.org/10.18565/aig.2020.1suppl.63-68

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.